Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.32 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.32 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17468555 | 0.90 | MAPK1 (0.34) | LMNAMAPK1POLBKMT2AALDH1A1 | |
| SCHEMBL19339212 | 0.90 | MAPK1 (0.34) | LMNAMAPK1POLBKMT2AALDH1A1 | |
| SCHEMBL17459552 | 0.90 | MAPK1 (0.34) | LMNAMAPK1POLBKMT2AALDH1A1 | |
| SCHEMBL17459553 | 0.90 | MAPK1 (0.34) | LMNAMAPK1POLBKMT2AALDH1A1 | |
| SCHEMBL601625 | 0.84 | KMT2A (0.33) | LMNAMAPK1CHRM4CHRM5CHRM1 | |
| SCHEMBL4746698 | 0.83 | EPHX2 (0.37) | LMNAMAPK1POLB | |
| SCHEMBL22167302 | 0.82 | ALDH1A1 (0.30) | CHRM4CHRM5CHRM1ALDH1A1 | |
| SCHEMBL13130604 | 0.81 | SMN1; SMN2 (0.35) | LMNAMAPK1CACNB4CACNA1ACACNA1G | |
| SCHEMBL20727192 | 0.81 | GRIN1 (0.33) | LMNAMAPK1POLBKMT2ATSHR | |
| SCHEMBL3017741 | 0.79 | MEN1 (0.36) | CHRM4CHRM5CHRM1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212523-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4650351-A1 | INHIBITOR OF COMPLEMENT FACTOR B | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250333408-A1 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12384775-B2 | Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4496794-A1 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-119301121-A | Pyrimidin-2-yl-pyrazole compounds as IRAK inhibitors | 里格尔药品股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-117209489-B | IRAK kinase inhibitors | 杭州邦顺制药有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024149261-A1 | INHIBITOR OF COMPLEMENT FACTOR B | 南京正大天晴制药有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-11993594-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-11939317-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
| EP-2004182-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| EP-1996188-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008119713-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119713-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | LMNA 3499/4885MAPK1 1242/4885POLB 3507/4885 |
| US-12384775-B2 | Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors | IRAK2, IRAK3, IRAK1 | LMNA 1800/4885MAPK1 374/4885POLB 2255/4885 |
| US-20250333408-A1 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | LMNA 1800/4885MAPK1 374/4885POLB 2255/4885 |
| US-11939317-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | LMNA 2345/4885MAPK1 432/4885POLB 3923/4885 |
| US-11993594-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | LMNA 1789/4885MAPK1 570/4885POLB 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.